A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.
about
Recent progress on nutraceutical research in prostate cancer.Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer.Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial.Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials.Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survivalChallenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy.Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer.Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.PPARgamma: The Portrait of a Target Ally to Cancer Chemopreventive AgentsMulti-targeted therapy of cancer by genisteinClinical development of novel proteasome inhibitors for cancer treatment.Role of phytoestrogens in cancer therapy.Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention.Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer.Does equol production determine soy endocrine effects?Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update.Phytoestrogens and risk of prostate cancer: a meta-analysis of observational studies.Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2.Food-based natural products for cancer management: Is the whole greater than the sum of the parts?Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model.
P2860
Q33818800-978725A3-58F1-45D4-B95C-BBA71E5159FEQ34284547-1B840114-2547-4652-AC98-BB7E8BAC6EE3Q34357401-B44532C7-7D4C-4CB0-A818-1728B357A6AAQ34848018-9C45AC77-A240-4B64-83DD-4346500B3DC2Q34992997-3A4A49CB-1BCF-427A-8537-85ADC038F15EQ35054256-BCD433B4-7573-4C89-9963-28B785CA6F26Q35713404-85988E8F-3DAB-461E-B9BC-7F7708BE9AEBQ35752245-C4CA3B3A-294F-4D46-930A-84A35AD9FE4EQ35761033-9E6BB354-4F77-4D7F-A761-C8911C4D6EC3Q35823852-47E2DF35-E2B3-4BF0-80A0-0EB262F7F5E3Q36249153-36E82C33-7A08-4199-923A-CB550DCE0A72Q36859555-EF64F8C7-0EA9-4E41-87FB-73816D717AC7Q36955543-ED9A62A8-7627-4B73-847A-A2609D4EFE9EQ37136598-4D36B499-5F01-4CE2-A40D-9D1811B53EE2Q37238391-B0C3906D-7488-4076-AEA5-FFCB7F63E7DFQ37380366-744E24A8-7427-4541-A57A-1FC2A006E03FQ37576761-542F0A11-1DF8-4602-853A-4D9748699D97Q37783352-4F95933F-676E-44E3-B19E-7F34C6B92803Q37988309-AD5F9A04-11F0-43CE-9488-CCEC43436D0FQ38245598-EC8A11B4-6E09-4240-AE3C-6BF664BB7C82Q38558029-3D933180-55E1-4E1C-A1B9-E8A391DF06D7Q38777429-887729A0-B272-4A01-849D-6F2F0DEC563EQ38891659-ACC88E81-7FA4-4888-930C-55D5FAB32D00Q42137006-8021842F-F0C0-44A8-9F10-BD9B55A7D1DE
P2860
A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A Phase II randomized, placebo ...... ith localized prostate cancer.
@ast
A Phase II randomized, placebo ...... ith localized prostate cancer.
@en
type
label
A Phase II randomized, placebo ...... ith localized prostate cancer.
@ast
A Phase II randomized, placebo ...... ith localized prostate cancer.
@en
prefLabel
A Phase II randomized, placebo ...... ith localized prostate cancer.
@ast
A Phase II randomized, placebo ...... ith localized prostate cancer.
@en
P2093
P2860
P1433
P1476
A Phase II randomized, placebo ...... ith localized prostate cancer.
@en
P2093
Diane Riccardi
Jeffrey P Krischer
Julio Pow-Sang
Karen Besterman-Dahan
Kathy Allen
Lovellen Kang
Nagi B Kumar
Raoul Salup
P2860
P304
P356
10.1080/01635580701432678
P577
2007-01-01T00:00:00Z